## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.4% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($433.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Alnylam Pharmaceuticals Announces Changes to Board of Directors**
- Source: Business Wire | 20251203T230938 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals announced changes to its Board of Directors, with Mike Bonney and Carolyn Bertozzi stepping down effective December 2, 2025. The company also appointed Stuart Arbuckle as a new independent director, effective January 5, 2026, bringing extensive biopharmaceutical commercialization experience to support Alnylam's strategic evolution and growth.

**2. Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years**
- Source: Sahm | 20251203T051222 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (NASDAQ: ALNY) has significantly outperformed the market over the last 20 years, generating an average annual return of 19.31%. An initial investment of $1000 in ALNY stock 20 years ago would now be worth over $34,000, showcasing the power of compounded returns. This analysis highlights the substantial growth experienced by long-term investors in Alnylam Pharmaceuticals.

**3. Alnylam Pharmaceuticals Announces Changes to Board of Directors**
- Source: Yahoo Finance | 20251203T080000 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals announced changes to its Board of Directors, with Mike Bonney and Carolyn Bertozzi, Ph.D. stepping down and Stuart Arbuckle joining as a new independent director. Mr. Bonney provided guidance through significant growth, and Dr. Bertozzi offered scientific oversight. Mr. Arbuckle brings extensive biopharmaceutical commercialization experience, which will support Alnylam's strategic evolution and pipeline advancement.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Wells Fargo | $479 | $395 | +21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +3.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 41.6x attractive for 126% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 46% YoY. Analyst sentiment positive (1 raises, avg +21%). Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $52.9B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 41.6 |
| Current P/E | 93.9 |
| YoY Growth | 125.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -1.9% to 1.4% (+3.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (3.02), confirming momentum. RSI neutral at 56. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.38% (CS: 66) | Neutral |
| RSI_14 | 56.1 | Neutral |
| MACD Histogram | 3.02 | Bullish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.305x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $465.34
- **Stop Loss:** $433.36 (6.9% risk)
- **Target:** $497.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 15
- **Position Value:** $6,980.10
- **Portfolio %:** 6.98%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*